Cargando…

Body Weight Counts—Cardioversion with Vernakalant or Ibutilide at the Emergency Department

Aim: Medication for the pharmacological cardioversion of atrial fibrillation (AF) and atrial flutter (AFL) is applied either in a fixed dose or adapted to body weight. Individual body weight might be a relevant confounder for anti-arrhythmic treatment success. Therefore, the aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindmayr, Teresa, Schnaubelt, Sebastian, Sulzgruber, Patrick, Simon, Alexander, Niederdoeckl, Jan, Cacioppo, Filippo, Schuetz, Nikola, Domanovits, Hans, Spiel, Alexander Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456766/ https://www.ncbi.nlm.nih.gov/pubmed/36078991 http://dx.doi.org/10.3390/jcm11175061

Ejemplares similares

Vernakalant and electrical cardioversion for AF – Safe and effective
por: Simon, Alexander, et al.
Publicado: (2019)

Cardioversion of Post-Ablation Atrial Tachyarrhythmia with Ibutilide and Amiodarone: A Registry-Based Cohort Study
por: Cacioppo, Filippo, et al.
Publicado: (2022)

Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department()
por: Simon, Alexander, et al.
Publicado: (2017)

The Impact of the COVID-19 Pandemic on Incidences of Atrial Fibrillation and Electrical Cardioversion at a Tertiary Care Emergency Department: An Inter- and Intra-year Analysis
por: Schnaubelt, Sebastian, et al.
Publicado: (2020)

Hyperkalemia: A persisting risk. A case report and update on current management
por: Schnaubelt, Sebastian, et al.
Publicado: (2020)

Hemodynamic effects of Vernakalant in cardio-surgical ICU-patients treated for recent-onset postoperative atrial fibrillation
por: Schnaubelt, S., et al.
Publicado: (2020)

Ibutilide for pharmacological cardioversion of atrial flutter
por: Magnusson, K, et al.
Publicado: (2002)

Association of Intravenous Potassium and Magnesium Administration With Spontaneous Conversion of Atrial Fibrillation and Atrial Flutter in the Emergency Department
por: Cacioppo, Filippo, et al.
Publicado: (2022)

Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study
por: Lévy, Samuel, et al.
Publicado: (2020)

Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department: The SPECTRUM Study
por: Bager, Johan-Emil, et al.
Publicado: (2022)

Prediction of Successful Pharmacological Cardioversion in Acute Symptomatic Atrial Fibrillation: The Successful Intravenous Cardioversion for Atrial Fibrillation (SIC-AF) Score
por: Niederdöckl, Jan Daniel, et al.
Publicado: (2022)

Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update
por: Tsuji, Yukiomi, et al.
Publicado: (2013)

Cardiac biomarkers predict mortality in emergency patients presenting with atrial fibrillation
por: Niederdöckl, Jan, et al.
Publicado: (2019)

Ibutilide with magnesium for conversion of atrial fibrillation or flutter in rheumatic heart disease patients: Ibutilide with magnesium for chemical cardioversion of atrial fibrillation or flutter
por: Malviya, Amit, et al.
Publicado: (2020)

Expert Opinion: Meditation and Cardiovascular Health: What is the Link?
por: Schnaubelt, Sebastian, et al.
Publicado: (2019)

Ibutilide for the Cardioversion of Paroxysmal Atrial Fibrillation during Radiofrequency Ablation of Supraventricular Tachycardias
por: Polymeropoulos, Kostas, et al.
Publicado: (2011)

Comparison of clinical outcomes of Ibutilide-guided cardioversion and direct current synchronized cardioversion after radiofrequency ablation of persistent atrial fibrillation
por: Liu, Xing, et al.
Publicado: (2023)

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation: A protocol for systematic review and meta-analysis
por: Li, Hong, et al.
Publicado: (2022)

Introducing Vernakalant into Clinical Practice
por: Hall, Angela JM, et al.
Publicado: (2019)

Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia–Pacific Region: A Phase 3 Randomized Controlled Trial
por: Beatch, Gregory N., et al.
Publicado: (2017)

Ibutilide after unsuccessful electric electroversion of atrial fibrillation
por: Magnusson, K, et al.
Publicado: (2002)

The Feasibility of Ultra-Sensitive Phonocardiography in Acute Chest Pain Patients of a Tertiary Care Emergency Department (ScorED Feasibility Study)
por: Schnaubelt, Sebastian, et al.
Publicado: (2022)

Meta-analysis of effect of vernakalant on conversion of atrial fibrillation
por: Yan, He, et al.
Publicado: (2013)

BLS courses for refugees are feasible and induce commitment towards lay rescuer resuscitation
por: Schnaubelt, Sebastian, et al.
Publicado: (2021)

Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients
por: Rudiger, Alain, et al.
Publicado: (2014)

The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department
por: Niederdöckl, Jan, et al.
Publicado: (2022)

Increasing gap junction coupling suppresses ibutilide-induced torsades de pointes
por: RUAN, LEI, et al.
Publicado: (2014)

The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case report
por: Hammer, Andreas, et al.
Publicado: (2020)

Ibutilide protects against cardiomyocytes injury via inhibiting endoplasmic reticulum and mitochondrial stress pathways
por: Wang, Yu, et al.
Publicado: (2016)

Ultra-low-dose CT vs. chest X-ray in non-traumatic emergency department patients – a prospective randomised crossover cohort trial
por: Wassipaul, Christian, et al.
Publicado: (2023)

DC cardioversion of atrial fibrillation and atrial flutter in the emergency department: improving specialist protocols for the generalist
por: Carpenter, Alexander, et al.
Publicado: (2018)

Ethical considerations during critical care from an age-specific perspective
por: Sulzgruber, Patrick, et al.
Publicado: (2021)

Critical care during a pandemic —Are we prepared for the ethical dilemma?
por: Schnaubelt, Sebastian, et al.
Publicado: (2022)

The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?
por: A, John Camm MD
Publicado: (2014)

Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy
por: Kossaify, Antoine
Publicado: (2019)

Low-Dose Ibutilide Combined with Catheter Ablation of Persistent Atrial Fibrillation: Procedural Impact and Clinical Outcome
por: Sun, Xue-Rong, et al.
Publicado: (2019)

Ibutilide treatment protects against ER stress induced apoptosis by regulating calumenin expression in tunicamycin treated cardiomyocytes
por: Wang, Yu, et al.
Publicado: (2017)

“Wait and See” Approach to the Emergency Department Cardioversion of Acute Atrial Fibrillation
por: Doyle, Brian, et al.
Publicado: (2011)

Electrical cardioversion
por: Sucu, Murat, et al.
Publicado: (2009)

Electrogenic Cardioversion
por: Theodore, Joseph, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c0mlqmo6mvaarbmrsbces3jli7